Upgrade to Chrome Upgrade to Firefox Upgrade to Microsoft Edge Upgrade to Safari
Skip to content
  • Services
    • Overview
    • Global Market Access
    • Evidence Review & Synthesis
    • Health Economic Modelling
    • Health Technology Assessment
    • Data Science & Analytics
    • Operational Research
    • Policy & Health Systems
    • Value Communication
    • Overview
    • Global Market Access
    • Evidence Review & Synthesis
    • Health Economic Modelling
    • Health Technology Assessment
    • Data Science & Analytics
    • Operational Research
    • Policy & Health Systems
    • Value Communication
    • Global Market Access
    • Evidence Review & Synthesis
    • Health Economic Modelling
    • Health Technology Assessment
    • Data Science & Analytics
    • Policy & Health Systems
    • Operational Research
    • Value Communication
  • About
    • About HEOR
    • Our Ethos
    • Team
    • Case Studies
    • About HEOR
    • Our Ethos
    • Team
    • Case Studies
    • About HEOR
    • Our Ethos
    • Team
    • Case Studies
  • Insights
    • Industry Insights
    • News
    • Publications
    • Industry Insights
    • News
    • Publications
    • Insights
    • News
    • Publications
  • Join us
    • Our people
    • Learn & develop
    • Candidate journey
    • Latest vacancies
    • Our people
    • Learn & develop
    • Candidate journey
    • Latest vacancies
    • Our people
    • Learn & develop
    • Candidate journey
    • Latest vacancies
  • Contact

Meeting the challenge of virtual diabetes care: a consensus viewpoint on the positioning and value of oral semaglutide in routine clinical practice

Serum potassium as a predictor of adverse clinical outcomes in patients with increasing comorbidity burden

Exploring structural uncertainty and impact of health state utility values on lifetime outcomes in diabetes economic simulation models: findings from the ninth Mount Hood Diabetes Quality-of-Life Challenge

The value of insulin degludec in frail older adults with type 2 diabetes

One hundred years of insulin: value beyond price in type 2 diabetes mellitus

The cost‐effectiveness of dapagliflozin in treating high risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE‐TIMI 58 trial

Risk prediction of the diabetes missing million: identifying individuals at high risk of diabetes and related complications

Assessing the cost‐effectiveness of SGLT2i in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real‐world evidence

Evaluating the ability of economic models of diabetes to simulate new cardiovascular outcomes trials: a report on the ninth mount hood diabetes challenge

Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the UK

← previous
Next →
  • Services
  • Insights
  • Case studies
  • Services
  • Insights
  • Case studies
  • About us
  • Contact us
  • About us
  • Contact us
  • Privacy policy
  • Environmental policy
  • Privacy policy
  • Environmental policy
© 2026 Health Economics and Outcomes Research LTD, All Rights Reserved
GDPR verified badge
Science Based Targets initiative (SBTi) validation logo
EcoVadis Committed badge for ESG performance
Carbon disclosure toolkit badge
Cyber Essentials

WE ARE COMMITTED TO SCIENCE-BASED CLIMATE TARGETS VALIDATED BY THE SBTI

  • Services
    • Global Market Access
    • Evidence Review & Synthesis
    • Health Economic Modelling
    • Health Technology Assessment
    • Data Science & Analytics
    • Policy & Health Systems
    • Operational Research
    • Value Communication
  • About
    • About HEOR
    • Our Ethos
    • Team
    • Case Studies
  • Insights
    • Insights
    • News
    • Publications
  • Join us
    • Our people
    • Learn & develop
    • Candidate journey
    • Latest vacancies
  • Contact